Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use
CPT4 code
Name of the Procedure:
Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, intramuscular injection. Commonly known as the HPV vaccine or Cervarix.
Summary
The HPV vaccine is a protective shot against certain types of human papillomavirus (HPV), specifically types 16 and 18, which are known to cause cervical cancer. The vaccine is administered in a series of three shots over a six-month period for optimal protection.
Purpose
The HPV vaccine is designed to prevent infections caused by HPV types 16 and 18, which are responsible for approximately 70% of cervical cancer cases. The ultimate goal is to reduce the incidence of cervical cancer and its associated morbidity and mortality.
Indications
- Girls and women aged 9 to 26 years
- Prevention of cervical cancer
- Prevention of precancerous lesions in the cervix
Preparation
- No special fasting or medication adjustments are required.
- Patients should inform the healthcare provider of any allergies or adverse reactions to previous vaccines.
- It's advised to stay hydrated and eat a light meal before the appointment.
Procedure Description
- The patient is seated comfortably.
- The healthcare provider will clean the injection site, usually the upper arm.
- The vaccine is administered via an intramuscular injection.
- The patient will stay for about 15 minutes post-injection to monitor for any immediate adverse reactions.
- The series includes three doses: the initial dose, a second dose one month later, and a third dose six months after the first dose.
Duration
Each injection takes only a few minutes. The entire 3-dose schedule spans about six months.
Setting
The procedure is typically performed in an outpatient clinic or a doctor's office.
Personnel
- Primary Care Physician or Pediatrician
- Nurse or Medical Assistant
Risks and Complications
- Common: Pain, redness, or swelling at the injection site, mild fever, headache, fatigue.
- Rare: Severe allergic reactions (anaphylaxis), fainting.
Benefits
- High efficacy in preventing HPV types 16 and 18 infections.
- Significant reduction in the risk of developing cervical cancer and precancerous lesions.
- Protection typically starts about 1 to 2 weeks after the final dose.
Recovery
- Patients can usually resume normal activities immediately.
- It is advisable to monitor for any side effects and report them to the healthcare provider.
- Follow-up appointments should be kept to complete the dosing schedule.
Alternatives
- Quadrivalent HPV vaccine (protects against additional types of HPV).
- Regular cervical screening (Pap tests and HPV tests).
- Use of condoms to reduce HPV transmission, although not 100% effective in prevention.
Patient Experience
- Slight discomfort or pain at the injection site during and after the shot.
- Temporary soreness or swelling in the arm.
- Mild systemic symptoms like headaches or a mild fever may occur but generally resolve quickly.
- Pain management can include over-the-counter pain relievers, if necessary.